BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 22023140)

  • 1. Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles.
    Gurumurthy M; Mukherjee T; Dowd CS; Singh R; Niyomrattanakit P; Tay JA; Nayyar A; Lee YS; Cherian J; Boshoff HI; Dick T; Barry CE; Manjunatha UH
    FEBS J; 2012 Jan; 279(1):113-25. PubMed ID: 22023140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of Ddn, the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis involved in bioreductive activation of PA-824.
    Cellitti SE; Shaffer J; Jones DH; Mukherjee T; Gurumurthy M; Bursulaya B; Boshoff HI; Choi I; Nayyar A; Lee YS; Cherian J; Niyomrattanakit P; Dick T; Manjunatha UH; Barry CE; Spraggon G; Geierstanger BH
    Structure; 2012 Jan; 20(1):101-12. PubMed ID: 22244759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release.
    Singh R; Manjunatha U; Boshoff HI; Ha YH; Niyomrattanakit P; Ledwidge R; Dowd CS; Lee IY; Kim P; Zhang L; Kang S; Keller TH; Jiricek J; Barry CE
    Science; 2008 Nov; 322(5906):1392-5. PubMed ID: 19039139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles.
    Kim P; Zhang L; Manjunatha UH; Singh R; Patel S; Jiricek J; Keller TH; Boshoff HI; Barry CE; Dowd CS
    J Med Chem; 2009 Mar; 52(5):1317-28. PubMed ID: 19209889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor.
    Somasundaram S; Anand RS; Venkatesan P; Paramasivan CN
    BMC Microbiol; 2013 Oct; 13():218. PubMed ID: 24083570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824).
    Cherian J; Choi I; Nayyar A; Manjunatha UH; Mukherjee T; Lee YS; Boshoff HI; Singh R; Ha YH; Goodwin M; Lakshminarayana SB; Niyomrattanakit P; Jiricek J; Ravindran S; Dick T; Keller TH; Dartois V; Barry CE
    J Med Chem; 2011 Aug; 54(16):5639-59. PubMed ID: 21755942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular dynamic assisted investigation on impact of mutations in deazaflavin dependent nitroreductase against pretomanid: a computational study.
    Singh R; Shaheer M; Sobhia ME
    J Biomol Struct Dyn; 2023 Jul; 41(10):4421-4443. PubMed ID: 35574601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering.
    Lee BM; Harold LK; Almeida DV; Afriat-Jurnou L; Aung HL; Forde BM; Hards K; Pidot SJ; Ahmed FH; Mohamed AE; Taylor MC; West NP; Stinear TP; Greening C; Beatson SA; Nuermberger EL; Cook GM; Jackson CJ
    PLoS Pathog; 2020 Feb; 16(2):e1008287. PubMed ID: 32032366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in Mycobacteria and a subcellular fraction of human liver.
    Dogra M; Palmer BD; Bashiri G; Tingle MD; Shinde SS; Anderson RF; O'Toole R; Baker EN; Denny WA; Helsby NA
    Br J Pharmacol; 2011 Jan; 162(1):226-36. PubMed ID: 20955364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine.
    Chaudhari HK; Pahelkar A
    Infect Disord Drug Targets; 2019; 19(2):145-166. PubMed ID: 30324898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis.
    Fujiwara M; Kawasaki M; Hariguchi N; Liu Y; Matsumoto M
    Tuberculosis (Edinb); 2018 Jan; 108():186-194. PubMed ID: 29523322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824.
    Li X; Manjunatha UH; Goodwin MB; Knox JE; Lipinski CA; Keller TH; Barry CE; Dowd CS
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2256-62. PubMed ID: 18358721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of 2-Nitroimidazooxazine Derivatives as Deazaflavin-Dependent Nitroreductase (Ddn) Activators as Anti-Mycobacterial Agents Based on 3D QSAR, HQSAR, and Docking Study with In Silico Prediction of Activity and Toxicity.
    Gupta N; Vyas VK; Patel BD; Ghate M
    Interdiscip Sci; 2019 Jun; 11(2):191-205. PubMed ID: 28895050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis.
    Haver HL; Chua A; Ghode P; Lakshminarayana SB; Singhal A; Mathema B; Wintjens R; Bifani P
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5316-23. PubMed ID: 26100695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studies.
    Denny WA; Palmer BD
    Future Med Chem; 2010 Aug; 2(8):1295-304. PubMed ID: 21426020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of action of 5-nitrothiophenes against Mycobacterium tuberculosis.
    Hartkoorn RC; Ryabova OB; Chiarelli LR; Riccardi G; Makarov V; Cole ST
    Antimicrob Agents Chemother; 2014 May; 58(5):2944-7. PubMed ID: 24550336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis.
    Patterson S; Wyllie S; Stojanovski L; Perry MR; Simeons FR; Norval S; Osuna-Cabello M; De Rycker M; Read KD; Fairlamb AH
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4699-706. PubMed ID: 23856774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protonation state of F420H2 in the prodrug-activating deazaflavin dependent nitroreductase (Ddn) from Mycobacterium tuberculosis.
    Mohamed AE; Ahmed FH; Arulmozhiraja S; Lin CY; Taylor MC; Krausz ER; Jackson CJ; Coote ML
    Mol Biosyst; 2016 Apr; 12(4):1110-3. PubMed ID: 26876228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of 5-substitution on the electrochemical behavior and antitubercular activity of PA-824.
    Bollo S; Núñez-Vergara LJ; Kang S; Zhang L; Boshoff HI; Barry CE; Squella JA; Dowd CS
    Bioorg Med Chem Lett; 2011 Jan; 21(2):812-7. PubMed ID: 21168331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adduct Formation of Delamanid with NAD in Mycobacteria.
    Hayashi M; Nishiyama A; Kitamoto R; Tateishi Y; Osada-Oka M; Nishiuchi Y; Kaboso SA; Chen X; Fujiwara M; Inoue Y; Kawano Y; Kawasaki M; Abe T; Sato T; Kaneko K; Itoh K; Matsumoto S; Matsumoto M
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.